NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
Clinical Trials
8 trialsNCT02588404 2024-12-10
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT04331717 2022-05-02
BASH-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT04585932 2021-01-20
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02811809 2020-02-27
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT01422096 2018-07-19
CBS007
University of Virginia
Phase EARLY_PHASE1 Withdrawn
NCT02678520 2016-07-22
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
University of Kansas Medical Center
Phase 2 Withdrawn
NCT00244920 2012-05-28
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn